NeuroStim TMS

NeuroStim TMS operates as a provider of outpatient mental health treatment rather than primarily as a medical-device manufacturer or software company. Its core service is transcranial magnetic stimulation (TMS), a non-invasive treatment using magnetic pulses, with care described for depression and other conditions including anxiety, OCD, and PTSD. NeuroStim reported 10,000 One-Day TMS sessions by Jul 23, 2026, alongside more than 300,000 total treatment sessions. That adoption figure provides a concrete measure of its service activity, although it does not establish comparative market share or clinical superiority. Its individualized treatment plans, outpatient delivery, and insurance-covered treatment services place it within the broader behavioral-health and TMS clinic landscape.

NeuroStim TMS’s visible growth story is centered on expanding clinical service delivery and introducing a faster treatment format, rather than on disclosed venture financing. Founded in 2018, the Seattle-based company is listed in the 51–100 employee range and describes an outpatient-center model for TMS treatment. The key product inflection point was the Aug 26, 2025 launch of One-Day TMS, an accelerated, single-day depression treatment based on the ONE-D protocol and intermittent theta-burst stimulation. By Jul 23, 2026, the company reported 10,000 sessions delivered through this service and more than 300,000 treatment sessions across its operation. These milestones suggest the accelerated format has moved beyond launch into active clinical use, while the total-session figure signals an established treatment operation. The company is also recruiting for roles including Psychiatric Nurse Practitioners, consistent with a need to staff clinical services.